Tanshinone IIA exerts antitumor activity against vestibular schwannoma cells by inhibiting the expression of hypoxia-inducible factor-1α

  • Authors:
    • Ju Yeon Kim
    • Jae‑Jun Song
    • Byoung‑Mog Kwon
    • Jong Dae Lee
  • View Affiliations

  • Published online on: June 15, 2015     https://doi.org/10.3892/mmr.2015.3932
  • Pages: 4604-4609
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the effect of the herbal medicine, tanshinone IIA (Tan IIA), on vestibular schwannoma (VS) cells and assess the functional targets of Tan IIA. HEI‑193 cells and Nf2‑/‑mouse Schwann (SC4) cells were used to investigate the inhibitory effects of Tan IIA on VS. Cell viability was measured using an MTT assay and apoptosis was assessed by flow cytometry. Western blot analysis and reverse transcription quantitative polymerase chain reaction (RT‑qPCR) were performed to assess the expression of hypoxia‑inducible factor‑1α (HIF‑1α) and its signaling pathways. In addition, the effect of Tan IIA on HIF‑1α transcription was determined using a luciferase reporter assay. Schwannoma cell proliferation was observed to be inhibited as the Tan IIA concentration increased under normoxic and hypoxic conditions. Furthermore, Tan IIA induced apoptosis in the HEI‑193 cells and inhibited the protein expression of HIF‑1α in the HEI‑193 cells under hypoxia, thus repressing the transcriptional activity of HIF‑1α. The present study demonstrated that HIF‑1α is expressed in hypoxic VS cells and Tan IIA inhibits VS cells by suppressing the activity of HIF‑1α. In conclusion, these results indicate that Tan IIA is a potential chemotherapeutic agent for the treatment of VS.

Introduction

Vestibular schwannomas (VS) are benign tumors of the Schwann cell sheath, which originate on the vestibular branches of cranial nerve VIII. VS occur either sporadically or as the hallmark tumor of neurofibromatosis type 2 (NF2), which is an hereditary disease caused by loss of the NF2 gene. Current treatment options for VS are surgical excision, stereo-tactic radiation and observation. Knowledge of the molecular biology of VS and the development of novel medical therapeutic methods have advanced markedly in previous years (1).

Tanshinone IIA (Tan IIA) is a key component of Danshen, a traditional herbal medicine isolated from Salvia miltiorrhiza Bunge, which is used to treat cardiovascular diseases (2). Tan IIA exhibits anti-inflammatory and antioxidative properties, and inhibits various human cancer cell lines by inducing apoptosis or inhibiting angiogenesis (35). However, the inhibitory effects of Tan IIA on VS cells remain to be elucidated.

Hypoxia-inducible factor-1 (HIF-1) is a transcription factor composed of α and β subunits. The expression of HIF-1α is regulated by low oxygen tension, whereas HIF-1β is expressed constitutively (6). As intratumoral hypoxia is a common characteristic of solid tumors, HIF-1α is overexpressed in various types of human cancer (7). The activity of HIF-1α in cells correlates with tumor growth and angiogenesis (8); therefore, HIF-1α represents an attractive therapeutic target for the treatment of numerous types of cancer (9). However, its effect in benign tumors is unclear and, to the best of our knowledge, there are no studies regarding the association between VS and HIF-1α.

The present study aimed to assess the effect of Tan IIA on VS cells and evaluate the functional targets of Tan IIA.

Materials and methods

Isolation of Tan IIA

Tan IIA was isolated from extracts of the roots of Salvia miltiorrhiza Bunge (Danshen) using methanol. Briefly, 2 kg Danshen root was extracted with 4 liters methanol for five days. The supernatant was subsequently filtered through Whatman Grade 4 filter paper (Sigma-Aldrich, St. Louis, MO, USA). The filtrate was concentrated under reduced pressure and the residue was dissolved in ethyl acetate. The ethyl acetate soluble fractions were concentrated under a vacuum and the obtained residue (125 g) was subjected to column chromatography with silica gel 60 (Sigma-Aldrich). The column was packed with methylene chloride and the sample was loaded in methylene chloride. The sample was subsequently eluted with hexane, which was followed by consecutive elution with hexane, containing 2, 5, 8 and 10% ethyl acetate. Tan IIA was purified by recrystallization in hexane and ethyl acetate. The structure of the compound was determined using nuclear magnetic resonance (1H and 13C NMR; JEOL Ltd., Tokyo, Japan) and by comparison with authentic samples.

Cell culture

The HEI-193 cells, an immortalized VS cell line, and Nf2-/-mouse Schwann (SC4) cells were obtained from the House Research Institute (Los Angeles, CA, USA) and were maintained in Dulbecco's modified Eagle's medium (DMEM), containing 10% fetal bovine serum (FBS) and 100 U/ml penicillin/streptomycin. To prevent changes in cell morphology, the schwannoma cells were used at passage six. The cell number was calculated using a hemocytometer (Marienfeld-Superior, Lauda-Königshofen, Germany). Hypoxic conditions were induced in an incubator chamber (Billups-Rothenberg, Inc., San Diego, CA, USA), which was flushed with a mixture of 1% O2, 5% CO2 and 94% N2. For normoxic incubation, the gas contained 20% O2, 5% CO2 and 75% N2.

Cell proliferation assay

HEI-193 cells and SC4 cells were seeded into 96-well plates at 5×103 cells per well. Following incubation for 24 h, the culture medium was replaced with medium containing Tan IIA at 1, 3, 5, 7 or 10 µg/ml, with four wells per concentration. Following 24 h treatment, one of the plates was removed and 40 µl fresh 3-[4,5-Dimethylthiazol]-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) in 5 g/l phosphate-buffered saline (PBS) was added to each well. Following incubation for 4 h at 37°C, the culture medium was discarded and 100 µl dimethyl sulfoxide was added to each well. The plates were agitated at room temperature for 30 min to dissolve the formazan crystals and the optical density was measured at 595 nm using a micro-plate reader (VersaMax Microplate Reader with SoftMax Pro Software; Molecular Devices, LLC, Sunnyvale, CA, USA).

Annexin V/propidium iodide (PI) staining

Apoptosis was analyzed using an Annexin V assay kit (BD Pharmingen, San Diego, CA, USA). Briefly, the HEI-193 cells were plated at 7×103 cells per well into six-well plates. Following overnight attachment, the cells were treated with 2 or 4 µg/ml Tan IIA for 48 h. The floating cells in the medium were combined with the attached cells, which had been harvested by trypsinization. The cells were washed with cold PBS and resuspended in 1X binding buffer, containing 10 mM HEPES/NaOH (pH 7.4; BD Pharmingen), 140 mM NaCl and 2.5 mM CaCl2, at a density of 1×106 cells/ml. Next, the cell suspension was stained with Annexin V-fluorescein isothiocyanate (FITC) and PI, provided with the kit, at room temperature for at least 10 min in the dark. The cells were analyzed using a FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) within 1 h of staining. The data were analyzed using WinList 5.0 software (Verity Software House, Topsham, ME, USA).

Measurement of caspase 3 activity

The enzymatic activity of capase-3 was assessed using a caspase colorimetric assay kit (BioVision Inc., Milpitas, CA, USA), according to the manufacturer's instructions. Briefly, the cells were rinsed twice with ice-cold PBS and lysed in lysis buffer (50 mM Tris-HCl, pH 8.0; 150 MM sodium citrate; 1% NP-40; 0.5% sodium deoxycholate; 0.1% sodium dodecyl sulfate) for 10 min on ice. The lysed cells were centrifuged at 10,000 × g for 5 min and an equal quantity of total protein in each lysate was quantified using a Lowry protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Cell lysates were incubated with 50 µl 2X reaction buffer, containing 10 mM dithiothreitol and 200 µM DEVD-pNA substrate at 37°C for 1.5 h. The absorbance was measured at a wavelength of 405 nm on a spectrophotometer.

Reverse-transcription quantitative polymerase chain reaction (RT-qPCR)

To assess the mRNA expression levels, total RNA was isolated using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. Total RNAs (3 µg) were reverse-transcribed at 55°C for 30 min and the cDNAs were amplified by 35 cycles in a PCR mixture (Qiagen Inc., Valencia, CA, USA). The oligo-nucleotide primers used in the PCR reactions were determined from the human HIF-1α sequence and β-actin, and were as follows: Forward, 5′-CCCCAGATTCAGGATCAGACA-3′ and reverse, 5′-CCATCATGTTCCATTTTTCG-3′ for HIF-1α, (701 bp fragment). The mRNA expression levels were normalized against β-actin. The PCR products were electro-phoresed on 1% agarose gels containing ethidium bromide and scanned using a PCR system (2720 Thermal Cycler; Applied Biosystems Life Technologies, Foster City, CA, USA).

Western blot analysis

To assess the protein expression levels, the cells at 80–90% confluence were starved by culturing in 0.2% FBS in DMEM for a further 20 h. The cells were stimulated with Tan IIA for 48 h and then rinsed twice in PBS (pH 7.4). The cells were lysed on ice for 30 min in radioim-munoprecipitation buffer [50 mM Tris (pH 7.5), 50 mM NaCl, 0.1% SDS, 1% Triton X-100 and 1% sodium deoxycholate], centrifuged at 11,700 x g for 30 min at 4°C and the insoluble materials were collected. The protein concentration was determined using the Lowry protein assay (Bio-Rad Laboratories, Inc.). The supernatant (30 µg) was separated on 6–12% acryl-amide gels (Bio-Rad Laboratories, Inc.) and the proteins were transferred onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked for 30 min at room temperature in Tris-buffered saline, containing 5% non-fat milk and 0.1% Tween 20. The proteins were detected by immunoblotting using the following specific primary antibodies: Monoclonal mouse anti-human HIF-1α (1:500; cat. no. 610958; BD Biosciences), polyclonal rabbit anti-human caspase-3 (1:1,000; cat. no. 9661; Cell Signaling Technology, Inc., Danvers, MA, USA) polyclonal rabbit anti-human phosphorylated-AKT (1:1,000; cat. no. sc-7985R; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), polyclonal rabbit anti-human total AKT (1:1,000; cat. no. 9272; Cell Signaling Technology, Inc.), polyclonal rabbit anti-human phosphorylated-extracellular signal-regulated kinases (ERKs) (1:1,000; cat. no. 9101; Cell Signaling Technology, Inc.), polyclonal rabbit anti-human total ERK (1:1,000; cat. no. 9102; Cell Signaling Technology, Inc.), and monoclonal mouse anti-human α-tubulin (1:5,000; cat. no. CP06; EMD Millipore) overnight at 4°C. Following incubation with the primary antibodies, the membranes were washed three times with Tris-buffered saline containing 0.1% Tween 20, and incubated with horseradish peroxidase-conjugated goat anti-rabbit (1:3,000; cat. no. sc-2004) and goat anti-mouse (1:3,000; cat. no. sc-2005) secondary antibodies (Santa Cruz Biotechnology, Inc.) for 1 h at room temperature. Detection was performed using an ECL-Plus western blotting detection system (GE Healthcare Life Sciences, Piscataway, NJ, USA).

Luciferase reporter assay

To examine the transcription of HIF-1, the HEI-193 cells were transfected with the firefly lucif-erase reporter plasmid, pGL 4.42 [luc2P/HRE/Hygro]. The HEI-193 cells were plated into DMEM, containing 10% FBS, in a 12-well plate. The cells were transiently transfected with 1 µg luciferase reporter plasmid (Promega Corporation, Madison, WI, USA), along with the desired combination of expression plasmids, using Lipofectamine Plus (Invitrogen Life Technologies), according to the manufacturer's instructions. Following incubation for 6 h, the cells were rinsed and provided fresh 10% FBS/DMEM. Following stabilization, the cells were treated for 24 h with Tan IIA (1 or 3 µg/ml) and were subsequently washed with PBS, lysed with passive lysis buffer and the luciferase activity was measured. The experiments were performed a minimum of three times. The luciferase activity was measured using the dual-luciferase assay system (Promega Corporation) using a luminometer (PerkinElmer, Inc., Waltham, MA, USA).

Statistical analysis

All data are presented as the mean ± standard deviation from three independent experiments. Statistical analysis by Student's t-test was performed using SPSS 13.0 software for Windows (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Inhibitory effect of Tan IIA on schwannoma cells

An MTT assay was used to detect the inhibitory effect of Tan IIA on the HEI-193 and SC4 cells. Cell proliferation of the HEI-193 and SC4 cells was inhibited as the concentration of Tan IIA increased from 1 to 10 µg/ml under normoxic and hypoxic conditions (Fig. 1). All experiments were repeated a minimum of three times and revealed similar results.

Tan IIA induces apoptosis in schwannoma cells

To demonstrate the induction of apoptosis by Tan IIA, western blotting and flow cytometric analysis with Annexin V/PI staining were performed. Caspase-3 has previously been associated with apoptotic changes in Tan IIA-induced cell death. Tan IIA activated the cleavage of caspase-3 under hypoxic conditions, which is a hallmark of apoptotic activation (Fig. 2A). Exposure to 1 or 3 µg/ml Tan IIA increased the activity of caspase-3 when compared with the untreated control (Fig. 2B). Following flow cytometric analysis, the PI fluorescence was plotted over the Annexin V-FITC fluorescence (Fig. 2C). Using this method, healthy cells exhibited low levels of FITC and PI fluorescence, whereas early apoptotic cells exhibited strong FITC fluorescence, but low PI fluorescence. By contrast, late apoptotic cells exhibited strong FITC and PI fluorescence, whereas dead cells exhibited low levels of FITC fluorescence and strong PI fluorescence. The proportions (%) of apoptotic cells (Q2 + Q4) were significantly higher in the HEI-193 cells that were exposed to 2 and 4 µg/ml Tan IIA (Fig. 2D).

Tan IIA attenuates the protein expression of HIF-1α in schwannoma cells under hypoxia

The effect of Tan IIA on the expression of HIF-1α in the HEI-193 cells was assessed. The HIF-1α protein was not expressed in the HEI-193 cells under normoxic conditions and following a 4-h exposure to hypoxia, the expression of HIF-1α was markedly increased in the HEI-193 cells. Tan IIA decreased the hypoxia-induced protein expression of HIF-1α in the HEI-193 cells (Fig. 3A). However, Tan IIA treatment did not alter the mRNA expression of HIF-1α in the HEI-193 cells under normoxic and hypoxic conditions (Fig. 3B). AKT and ERK (upstream modulators of HIF-1α) signaling was not altered by treatment with Tan IIA (Fig. 3C).

Tan IIA attenuates HIF-1α promoter activity in schwannoma cells under hypoxia

The HEI-193 cells were treated with 1 or 3 µg/ml Tan IIA under hypoxic conditions for 4 h. The hypoxia response element (HRE) promoter activity in HEI-193 cells following a 24-h incubation period was assessed using a luciferase reporter assay with the luc2P/HRE/Hygro construct. The expression of HRE-regulated luciferase reporter gene was reduced following treatment with Tan IIA, suggesting that Tan IIA was able to inhibit the translational activity fo HIF-1α (Fig. 4).

Discussion

Although there is currently no approved medical therapeutic strategy for VS, various chemotherapeutic agents have been developed based on the underlying biology of schwannomas. Various previous studies have attempted to inhibit the growth of schwannomas by suppressing various receptor tyrosine kinases, including ErbB family receptors, vascular endothelial growth factors and their downstream mediators, including the MAPK/ERK and PI3K/AKT signaling pathways (10). However, the emerging medications for treating schwannomas are the chemotherapeutic agents that are administered for treating cancer, and the cost and toxicity associated with these agents for treating a VS benign tumor complicates their clinical use.

Numerous natural products appear to protect against cancer by interfering with multiple cell signaling pathways (11). Danshen, a herbal drug derived from the dried root or rhizome of Salvia miltiorrhiza Bunge, has been administered clinically in China and certain other Asian countries to prevent or manage cardiovascular disease (2). Tan IIA is a lipid-soluble phenolic compound and the most abundant component of Danshen. Previous studies have revealed that Tan IIA inhibits the growth and induces the apoptosis of various human cancer cell models, including breast cancer (12), leukemia cells (13), human lung cancer cells (14), colon cancer cells (15) and hepatocellular carcinoma cells (16). The present study demonstrates for the first time, to the best of our knowledge, that Tan IIA inhibits the growth of VS cells. Using flow cytometry and caspase-3 activity to detect apoptosis, it was revealed that Tan IIA induces apoptosis in HEI-193 cells.

As the master regulator of the hypoxic transcriptional response, HIF-1α is central in tumor growth and angiogenesis (17). HIF-1α is overexpressed in various types of human cancer, including brain, breast, colon, lung, ovary and prostate (18). Although little is known about the impact of HIF-1α in benign tumors, the present study revealed that HIF-1α is expressed in VS cells under hypoxic conditions. Therapeutic agents that target HIF-1a have the potential to target multiple cancer processes, and numerous chemical inhibitors of HIF-1α have been developed. In addition, certain natural products inhibit the activity of HIF-1α in various types of cancer cell (19). Although it was reported that Tan IIA reduced lipopolysaccharide-induced lung injury by inhibiting the HIF-1α signaling pathway (20), the molecular mechanism of its antitumor activity under hypoxia remains to be elucidated. The present study demonstrates that Tan IIA decreases the hypoxia-induced expression of HIF-1α in HEI-193 cells.

The protein expression of HIF-1α is tightly regulated via protein degradation and synthesis. The present study revealed that Tan IIA does not alter the mRNA expression of HIF-1α in HEI-193 cells under hypoxic conditions. The results indicated that Tan IIA inhibits the expression of HIF-1α at the translational level. It was also demonstrated that Tan IIA inhibits the activity of HIF-1α under hypoxic conditions, as assessed using a luciferase reporter assay. However, the potential mechanisms, including protein degradation and DNA binding activity are currently being investigated.

Previous studies have reported that various signaling pathways regulate HIF-1α, including the PI3K/AKT/mTOR and MAPK signaling pathways (2123). Certain compounds inhibit the expression of HIF-1α via the PI3K/AKT/mTOR signaling pathways. In addition, ERK and c-Jun N-terminal kinases signaling are involved in the regulation of HIF-1α. However, the present study demonstrated that Tan IIA exerted a marginal effect on inhibiting these signaling pathways.

Although the present study is limited by its in vitro nature, further investigation, including clinical trials of human schwan-noma, may be considered since Tan IIA has been administered safely for the treatment of various human diseases, such as chronic renal failure and coronary heart disease.

In conclusion, the present study provides evidence that HIF-1α is expressed in hypoxic VS cells and that Tan IIA inhibits VS cells by suppressing the activity of HIF-1α. These findings indicated that Tan IIA may be considered as a chemotherapeutic agent for the treatment of VS.

Acknowledgments

The present study was supported by the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology (grant no. 2013R1A1A2010381) and the Soonchunhyang University Research Fund. The authors would like to thank Dr M. Giovannini (UCLA, Los Angeles, CA, USA) for providing the HEI-193 and SC4 cells.

References

1 

Theodosopoulos PV and Pensak ML: Contemporary management of acoustic neuromas. Laryngoscope. 121:1133–1137. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Zhou L, Zuo Z and Chow MS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Fan GW, Gao XM, Wang H, Zhu Y, Zhang J, Hu LM, Su YF, Kang LY and Zhang BL: The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol. 113:275–280. 2009. View Article : Google Scholar : PubMed/NCBI

4 

Wang AM, Sha SH, Lesniak W and Schacht J: Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminogly-coside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother. 47:1836–1841. 2003. View Article : Google Scholar : PubMed/NCBI

5 

Dong Y, Morris-Natschke SL and Lee KH: Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Nat Prod Rep. 28:529–542. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar

7 

Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI

8 

Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI

9 

Poon E, Harris AL and Ashcroft M: Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med. 11:e262009. View Article : Google Scholar : PubMed/NCBI

10 

Sughrue ME, Yeung AH, Rutkowski MJ, Cheung SW and Parsa AT: Molecular biology of familial and sporadic vestibular schwannomas: Implications for novel therapeutics. J Neurosurg. 114:359–366. 2011. View Article : Google Scholar

11 

Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J and Wang W: Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer. 116:799–807. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Liu JJ, Lin DJ, Liu PQ, Huang M, Li XD and Huang RW: Induction of apoptosis and inhibition of cell adhesive and invasive effects by tanshinone IIA in acute promyelocytic leukemia cells in vitro. J Biomed Sci. 13:813–823. 2006. View Article : Google Scholar : PubMed/NCBI

14 

Chiu TL and Su CC: Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI

15 

Su CC, Chen GW and Lin JG: Growth inhibition and apoptosis induction by tanshinone I in human colon cancer Colo 205 cells. Int J Mol Med. 22:613–618. 2008.PubMed/NCBI

16 

Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF and Zhang J: Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol. 10:2024–2028. 2004.PubMed/NCBI

17 

Semenza GL: HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med. 8(4 Suppl): S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI

18 

Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI

19 

Nagle DG and Zhou YD: Natural product-based inhibitors of hypoxia-inducible factor 1 (HIF-1). Curr Drug Targets. 7:355–369. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Xu M, Cao F, Liu L, Zhang B, Wang Y, Dong H, Cui Y, Dong M, Xu D, Liu Y, et al: Tanshinone IIA-induced attenuation of lung injury in endotoxemic mice is associated with reduction of hypoxia-inducible factor 1vα expression. Am J Respir Cell Mol Biol. 45:1028–1035. 2011. View Article : Google Scholar : PubMed/NCBI

21 

Minet E, Michel G, Mottet D, Raes M and Michiels C: Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic Biol Med. 31:847–855. 2001. View Article : Google Scholar : PubMed/NCBI

22 

Xia Y, Choi HK and Lee K: Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem. 49:24–40. 2012. View Article : Google Scholar : PubMed/NCBI

23 

Melillo G: Targeting hypoxia cell signaling for cancer therapy. Cancer metastasis Rev. 26:341–352. 2007. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2015
Volume 12 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kim, J.Y., Song, J., Kwon, B., & Lee, J.D. (2015). Tanshinone IIA exerts antitumor activity against vestibular schwannoma cells by inhibiting the expression of hypoxia-inducible factor-1α. Molecular Medicine Reports, 12, 4604-4609. https://doi.org/10.3892/mmr.2015.3932
MLA
Kim, J. Y., Song, J., Kwon, B., Lee, J. D."Tanshinone IIA exerts antitumor activity against vestibular schwannoma cells by inhibiting the expression of hypoxia-inducible factor-1α". Molecular Medicine Reports 12.3 (2015): 4604-4609.
Chicago
Kim, J. Y., Song, J., Kwon, B., Lee, J. D."Tanshinone IIA exerts antitumor activity against vestibular schwannoma cells by inhibiting the expression of hypoxia-inducible factor-1α". Molecular Medicine Reports 12, no. 3 (2015): 4604-4609. https://doi.org/10.3892/mmr.2015.3932